208 related articles for article (PubMed ID: 34377590)
21. Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology.
Muraro E; Romanò R; Fanetti G; Vaccher E; Turturici I; Lupato V; La Torre FB; Polesel J; Fratta E; Giacomarra V; Franchin G; Steffan A; Spina M; Alfieri S
Crit Rev Oncol Hematol; 2022 Jul; 175():103707. PubMed ID: 35569724
[TBL] [Abstract][Full Text] [Related]
22. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
[TBL] [Abstract][Full Text] [Related]
23. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
24. Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma.
Ma B; Jiang H; Luo Y; Liao T; Xu W; Wang X; Dong C; Ji Q; Wang Y
Front Immunol; 2021; 12():692079. PubMed ID: 34737735
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.
Lim SM; Hong MH; Ha SJ; Hwang D; Chae S; Koh YW; Choi EC; Kim SH; Kim DH; Yoon SO; Kim HR
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2741-2750. PubMed ID: 33616718
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Segal NH; Ou SI; Balmanoukian A; Fury MG; Massarelli E; Brahmer JR; Weiss J; Schöffski P; Antonia SJ; Massard C; Zandberg DP; Khleif SN; Xiao F; Rebelatto MC; Steele KE; Robbins PB; Angra N; Song X; Abdullah S; Butler M
Eur J Cancer; 2019 Mar; 109():154-161. PubMed ID: 30731276
[TBL] [Abstract][Full Text] [Related]
27. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
Tsai MS; Chen WC; Lu CH; Chen MF
Oral Oncol; 2019 Apr; 91():47-55. PubMed ID: 30926062
[TBL] [Abstract][Full Text] [Related]
28. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
29. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
30. [Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
Yang LS; Shi CY; Liang YH; Liu T; Hou XR; Tian XD; Wang XY
Hua Xi Kou Qiang Yi Xue Za Zhi; 2019 Oct; 37(5):516-520. PubMed ID: 31721500
[TBL] [Abstract][Full Text] [Related]
31. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
32. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
34. A robust six-miRNA prognostic signature for head and neck squamous cell carcinoma.
Zhao X; Cui L
J Cell Physiol; 2020 Nov; 235(11):8799-8811. PubMed ID: 32342519
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
Zhang F; Liu Y; Yang Y; Yang K
BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.
Jiang S; Li X; Huang L; Xu Z; Lin J
Front Immunol; 2022; 13():988416. PubMed ID: 36119046
[TBL] [Abstract][Full Text] [Related]
37. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
Moratin J; Metzger K; Safaltin A; Herpel E; Hoffmann J; Freier K; Hess J; Horn D
Head Neck; 2019 Aug; 41(8):2484-2491. PubMed ID: 30821864
[TBL] [Abstract][Full Text] [Related]
39. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC
Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]